Home›Clinical trials›A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Enrolling now · NCT06948422

A study testing whether a GLP-1 medicine from Lilly, orforglipron, can lower blood pressure.

What this means for you

Who can join
Adults 18+, have high blood pressure, BMI 25+.
What you take
orforglipron, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
How long it lasts
The full study runs about 2.4 years; your own time in it is usually shorter.
What you get
The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
Phase Phase 3Sponsor Eli Lilly and CompanyDrug orforglipronClass GLP-1 RASites 29 USEnrollment target 974

What this study is for

Primary condition: Hypertension.

Full scientific study title: A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening).

Who can join

Age18 and upSexAnyBMI25 or higher

Adults 18+, have high blood pressure, BMI 25+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Has systolic blood pressure (SBP) >= 140 mmHg and/or diastolic blood pressure (DBP) >= 90 mmHg (if DBP criteria alone is met, SBP must be >=130 mmHg) at screening (Visit 1).
  • Has SBP >= 140 mmHg and/or DBP >= 90 mmHg (if DBP criteria alone is met, SBP must be >=130 mmHg) at week 0 (Visit 3).
  • Untreated for hypertension, or on stable antihypertensive medications >= 30 days prior to Visit 1.
  • Have a body mass index (BMI) >= 25 kg/m².

Key exclusion criteria

  • Has SBP >=170 mmHg and/or DBP >=110 mmHg at Visit 1 or at Visit 3.
  • Has known secondary causes of hypertension
  • Have heart failure with reduced ejection fraction (HFrEF) diagnosis
  • Have had any of the following conditions within 90 days prior to screening.
  • hospitalization for hypertension or for congestive heart failure

Where this study is enrolling

This trial has 29 sites across 18 states. Contact a site coordinator directly to start screening.

Arizona1 site
  • Elite Clinical Studies, LLC
    Phoenix, Arizona
California2 sites
  • Valley Clinical Trials, Inc.
    Covina, California
  • Valley Clinical Trials, Inc.
    Northridge, California
Connecticut1 site
  • Chase Medical Research, LLC
    Waterbury, Connecticut
Florida4 sites
  • Excel Medical Clinical Trials
    Boca Raton, Florida
  • Care Access - Brandon
    Brandon, Florida
  • Northeast Research Institute - Downtown Office
    Jacksonville, Florida
  • Care Access - St. Petersburg
    St. Petersburg, Florida
Hawaii1 site
  • East-West Medical Research Institute
    Honolulu, Hawaii
Maryland2 sites
  • Sinai Hospital Of Baltimore
    Baltimore, Maryland
  • Ascension Saint Agnes Heart Care
    Baltimore, Maryland
Massachusetts1 site
  • Lucida Clinical Trials
    New Bedford, Massachusetts
Michigan1 site
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
    Troy, Michigan
Missouri1 site
  • StudyMetrix Research
    City of Saint Peters, Missouri
Nevada2 sites
  • Excel Clinical Research, LLC
    Las Vegas, Nevada
  • Palm Research Center Sunset
    Las Vegas, Nevada
New York1 site
  • Rochester Clinical Research, LLC
    Rochester, New York
Ohio2 sites
  • Remington-Davis, Inc
    Columbus, Ohio
  • PriMED Clinical Research
    Dayton, Ohio
Oregon1 site
  • Advanced Research Institute - Tigard
    Tigard, Oregon
South Carolina1 site
  • Care Access - Mauldin
    Mauldin, South Carolina
Texas3 sites
  • Dallas Heart and Vascular Consultants, PA
    Duncanville, Texas
  • Texas Institute of Cardiology, PA
    McKinney, Texas
  • North Hills Family Medicine/North Hills Medical Research
    North Richland Hills, Texas
Utah1 site
  • Advanced Research Institute
    Ogden, Utah
Virginia3 sites
  • Carient Heart & Vascular - Manassas
    Manassas, Virginia
  • Health Research of Hampton Roads, Inc.
    Newport News, Virginia
  • National Clinical Research, Inc
    Richmond, Virginia
Washington1 site
  • Eastside Research Associates
    Redmond, Washington

Timeline

Started enrolling: 2025-04-30. Expected completion: 2027-09. Last updated on ClinicalTrials.gov: 2026-05-12.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact
Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page weekly.